Trial Profile
A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2024
Price :
$35
*
At a glance
- Drugs Luspatercept (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 12 Dec 2023 Results (n=95) evaluating the impact of Luspatercept on clinical parameters and transfusion burden in patients with MF, presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results assessing safety of Luspatercept in the Treatment of Anemia in Patients with Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 15 Jun 2023 Results presented at the 28th Congress of the European Haematology Association